Liquidia Corporation
- LQDA
- NASDAQ
- Medical - Pharmaceuticals
- Pulmonary Hypertension Treatments
- Biopharmaceuticals
- Rare Disease/Respiratory
$34.24
Today −0.32%Quote Oct 19, 2026, 07:40 PM UTC
−49.77%over the last month
Max drawdown −64.8%From 1-month high −53.4%3 months −55.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Liquidia
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension.
Where the money comes from
Q2 2026 revenue $171.7M
- Product$170.4M99.2%
- Service$1.3M0.8%
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Exchange
NASDAQ
Employees
216
Founded
2004
Market value
$3.06B
Quote Oct 19
Floor
$31.87
6.9% below price
Resistance
$34.38
0.4% above price
Price vs analyst targets
9 analysts
Lowest target
$33.00Highest target
$130.00
$33.00Highest target
$130.00
- Price $34.24
- Average target $72.36
- Analysts' target range
The price is close to the lowest analyst target. Analysts' average target sits about 111% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about LQDAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free